CN116761599B - 氘代或部分氘代的n,n-二甲基色胺化合物 - Google Patents

氘代或部分氘代的n,n-二甲基色胺化合物 Download PDF

Info

Publication number
CN116761599B
CN116761599B CN202180090269.1A CN202180090269A CN116761599B CN 116761599 B CN116761599 B CN 116761599B CN 202180090269 A CN202180090269 A CN 202180090269A CN 116761599 B CN116761599 B CN 116761599B
Authority
CN
China
Prior art keywords
compound
formula
compounds
pharmaceutically acceptable
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180090269.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN116761599A (zh
Inventor
P·兰德斯
E·詹姆斯
T·本威
Z·乔尔
M·雷泽尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Saiben Uk Ltd
Original Assignee
Saiben Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/108,938 external-priority patent/US20220169606A1/en
Priority claimed from GBGB2018955.1A external-priority patent/GB202018955D0/en
Priority claimed from GB2103981.3A external-priority patent/GB2605144A/en
Priority claimed from US17/208,583 external-priority patent/US11773062B2/en
Priority claimed from PCT/EP2021/060750 external-priority patent/WO2021116503A2/en
Priority claimed from US17/320,155 external-priority patent/US12042564B2/en
Application filed by Saiben Uk Ltd filed Critical Saiben Uk Ltd
Publication of CN116761599A publication Critical patent/CN116761599A/zh
Application granted granted Critical
Publication of CN116761599B publication Critical patent/CN116761599B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202180090269.1A 2020-12-01 2021-11-18 氘代或部分氘代的n,n-二甲基色胺化合物 Active CN116761599B (zh)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US17/108,938 2020-12-01
GB2018955.1 2020-12-01
US17/108,938 US20220169606A1 (en) 2020-12-01 2020-12-01 Compositions and compounds for bioanalysis
GBGB2018955.1A GB202018955D0 (en) 2020-12-01 2020-12-01 Compositions and compounds for bioanalysis
GB2103981.3A GB2605144A (en) 2021-03-22 2021-03-22 Deuterated compounds
US17/208,583 2021-03-22
US17/208,583 US11773062B2 (en) 2021-03-22 2021-03-22 Deuterated compounds
GB2103981.3 2021-03-22
PCT/EP2021/060750 WO2021116503A2 (en) 2020-06-02 2021-04-23 Deuterated compounds
EPPCT/EP2021/060750 2021-04-23
CA3118556A CA3118556A1 (en) 2020-06-02 2021-05-13 Therapeutic solid dosage forms
GB2106881.2 2021-05-13
CA3118556 2021-05-13
EPPCT/EP2021/062794 2021-05-13
PCT/EP2021/062794 WO2021244831A1 (en) 2020-06-02 2021-05-13 Therapeutic solid dosage forms
US17/320,155 US12042564B2 (en) 2020-06-02 2021-05-13 Therapeutic solid dosage forms
US17/320,155 2021-05-13
GB2106881.2A GB2595776B (en) 2020-06-02 2021-05-13 Therapeutic solid dosage forms
PCT/EP2021/082227 WO2022117359A1 (en) 2020-12-01 2021-11-18 Deuterated or partially deuterated n,n-dimethyltryptamine compounds

Publications (2)

Publication Number Publication Date
CN116761599A CN116761599A (zh) 2023-09-15
CN116761599B true CN116761599B (zh) 2025-05-30

Family

ID=88294961

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180090269.1A Active CN116761599B (zh) 2020-12-01 2021-11-18 氘代或部分氘代的n,n-二甲基色胺化合物

Country Status (8)

Country Link
EP (2) EP4275753B1 (https=)
JP (1) JP7834754B2 (https=)
CN (1) CN116761599B (https=)
AU (1) AU2021391581A1 (https=)
CA (1) CA3203020A1 (https=)
IL (1) IL303288A (https=)
TW (1) TWI891942B (https=)
WO (1) WO2022117359A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201907871D0 (en) * 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
CN114787363A (zh) 2019-10-01 2022-07-22 恩派瑞安神经科学公司 对真菌进行遗传工程化以调节色胺表达
JP7422473B2 (ja) 2019-11-07 2024-01-26 サイビン ユーケー リミテッド 合成方法
PH12022551981A1 (en) 2020-02-04 2023-10-16 Mindset Pharma Inc Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders
KR20240096817A (ko) 2020-05-19 2024-06-26 사이빈 아이알엘 리미티드 중수소화된 트립타민 유도체 및 사용 방법
US12042564B2 (en) 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
US12521370B2 (en) 2020-12-01 2026-01-13 Cybin Uk Ltd Inhalable formulations
US11660289B2 (en) 2020-12-01 2023-05-30 Small Pharma Ltd. Deuterated or partially deuterated N,N-dimethyltryptamine compounds
US12318477B2 (en) 2021-11-18 2025-06-03 Cybin Uk Ltd Injectable and inhalable formulations
MX2024005955A (es) * 2021-11-18 2024-06-11 Cybin Uk Ltd Formulaciones inyectables e inhalables.
EP4457336A4 (en) 2021-12-31 2026-01-14 Empyrean Neuroscience Inc ORGANISMS GENETICALLY MODIFIED TO PRODUCE PSYCHOTROPIC ALKALOIDS
US20250051279A1 (en) * 2022-01-14 2025-02-13 Cybin Irl Limited Tryptamine compositions and methods
US12264131B2 (en) * 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
CN120344243A (zh) 2022-10-13 2025-07-18 赛本英国有限公司 包含致幻剂的胃肠外制剂的施用方法
EP4618981A1 (en) 2022-11-17 2025-09-24 Remedi, Inc. Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use
WO2024156713A1 (en) 2023-01-23 2024-08-02 Cybin Uk Ltd Treatment of psychiatric or neurological disorders by parenteral administration of a single, effective parenteral dose of a short-acting psychedelic agent
AU2024242138A1 (en) 2023-03-31 2025-11-13 Cybin Uk Ltd Combination comprising a monoamine antidepressant agent and a short-duration psychedelic agent
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
WO2026013174A1 (en) 2024-07-10 2026-01-15 Cybin Uk Ltd Pharmaceutical compositions comprising deuterated n,n-dimethyltryptamine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019081764A1 (en) * 2017-10-26 2019-05-02 Consejo Superior De Investigaciones Científicas (Csic) ASSOCIATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND / OR PSYCHIATRIC DISORDERS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002520353A (ja) * 1998-07-16 2002-07-09 マサチューセッツ インスティテュート オブ テクノロジー ストレスの処置のための組成物
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
PH12022551981A1 (en) * 2020-02-04 2023-10-16 Mindset Pharma Inc Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders
WO2021234608A1 (en) * 2020-05-19 2021-11-25 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
AU2021204158B2 (en) * 2020-06-02 2023-03-02 Cybin Uk Ltd Deuterated compounds
EP3902541B1 (en) * 2020-06-02 2022-09-14 Small Pharma Ltd Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
US11000534B1 (en) * 2020-10-08 2021-05-11 Lennham Pharmaceuticals, Inc. Deuterated derivatives of psilocybin and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019081764A1 (en) * 2017-10-26 2019-05-02 Consejo Superior De Investigaciones Científicas (Csic) ASSOCIATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND / OR PSYCHIATRIC DISORDERS

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Deuterated drugs: where are we now?;Graham S Timmins;《Expert Opin. Ther. Patents》;第24卷(第10期);第1-9页 *
INDOLEALKYLAMINE METABOLISM. SYNTHESIS OF DEUTERATED INDOLEALKYLAMINES AS METABOLIC PROBES;Philip E. 等;《Journal of Labelled Compounds and Radiopharmaceuticals》(第6期);第455-465页 *

Also Published As

Publication number Publication date
JP7834754B2 (ja) 2026-03-24
CA3203020A1 (en) 2022-06-09
EP4275753B1 (en) 2026-03-18
JP2023551058A (ja) 2023-12-06
EP4031529C0 (en) 2023-09-27
CN116761599A (zh) 2023-09-15
EP4275753A2 (en) 2023-11-15
TWI891942B (zh) 2025-08-01
WO2022117359A1 (en) 2022-06-09
IL303288A (en) 2023-07-01
EP4275753A3 (en) 2023-12-27
AU2021391581A1 (en) 2023-07-06
EP4031529B1 (en) 2023-09-27
EP4031529A1 (en) 2022-07-27
TW202237565A (zh) 2022-10-01

Similar Documents

Publication Publication Date Title
CN116761599B (zh) 氘代或部分氘代的n,n-二甲基色胺化合物
US12251371B2 (en) Deuterated or partially deuterated N,N-dimethyltryptamine compounds
EP3844147B1 (en) Compounds
US11773062B2 (en) Deuterated compounds
EP4255421A1 (en) Inhalable formulations
US20220169606A1 (en) Compositions and compounds for bioanalysis
HK40103232A (en) Deuterated or partially deuterated n,n-dimethyltryptamine compounds
HK40078818B (en) Deuterated or partially deuterated n,n-dimethyltryptamine compounds
HK40078818A (en) Deuterated or partially deuterated n,n-dimethyltryptamine compounds
GB2605144A (en) Deuterated compounds
HK40056359A (en) Compounds
HK40056359B (en) Compounds
HK40060666B (en) Method of synthesis
HK40060666A (en) Method of synthesis
CN118450893A (zh) 可注射和可吸入的制剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Country or region after: United Kingdom

Address after: London

Applicant after: Saiben UK Ltd.

Address before: London

Applicant before: SMAR Pharmaceutical Co.,Ltd.

Country or region before: United Kingdom

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant